| 摘要 |
(I) wherein R1-R2, W and Y are as described m the specification, and their salts and pro-drugs, are inhibitors of DGAT and are thereby useful in the treatment of, for example, obesity. Processes for preparing compounds of formula (I) are also described.
|
